Dean Fennell is Professor & consultant in Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Programme based at the University of Leicester and University Hospitals of Leicester in the UK. He is an internationally recognised key opinion leader, clinical investigator and translational researcher with a focus on mesothelioma. He has led several investigator-initiated trials from phase 1 through to phase III. Prof. Fennell is member of the IASLC mesothelioma taskforce, steering committee for the British Lung Foundation mesothelioma research network, past president of the International Mesothelioma Interest Group, and co-author of the UK BTS, and European (ESMO, ERS) mesothelioma treatment guidelines. He is currently the Leicester lead for the ground breaking CRUK TraceRx/Darwin studies in lung cancer and BLF supported MEDUSA (mesothelioma) evolution studies. Prof. Fennell held two prestigious CRUK clinician scientist and MRC doctoral fellowships. He originally trained in pharmacology (1st class) and medicine at University College London where he was awarded several prizes. He completed medical training in the London Golden circuit (Hammersmith, Brompton, Guy's, St Thomas's), and completed his specialist training at Barts Hospital. Prof. Fennell has published over 100 peer reviewed articles in journals including The Lancet, Lancet Oncology, New England Journal of Medicine, Nature, Nature Reviews Cancer, and Proceedings of the National Academy of Sciences. 

Dr Paul Baas gained his medical degree in 1986 from the University of Amsterdam and trained for chest physician at the Free University. Currently, Dr Baas is head of the department of Thoracic Oncology at the Netherlands Cancer Institute in Amsterdam. He holds a PhD degree in Applied Medicine at the University of Amsterdam and has been appointed as a Professor in Thoracic Oncology at the University Hospital of Leiden. He has published over 250 peer reviewed papers and is involved in the several cancer research groups like the, ETOP, EORTC and ESMO. Since 1992 he focused on translational research as part of studies initiated in his clinic.

Dr. Christine Lovly is a physician-scientist with a special interest in thoracic malignancies. Dr. Lovly's clinical practice focuses primarily on the care of patients with lung cancer. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer. She is the author of several peer-reviewed scientific manuscripts, and she is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR). 

Dr. Horn is an Associate Professor of Medicine and the Clinical Director of the Thoracic Oncology Research Program at Vanderbilt Ingram Cancer Center (VICC) in Nashville TN. She is also the Assistant Vice Chairman for Faculty Development at Vanderbilt University Medical Center. Her clinical practice focuses on the care of patients with lung cancer. She is an active member of the Eastern Cooperative Oncology Group, International Association for the Study of Lung Cancer and the American Society of Clinical Oncology. She has over 1000 publications including in the New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology. In the last five years, she has been among the top 5 in accrual to clinical trials at VICC where she has a focus on clinical trials with targeted therapies and immunotherapy as well as small cell lung cancer. 

Dr. Misako Nagasaka is a thoracic oncologist and a clinical investigator at the Karmanos Cancer Institute, located in Detroit, Michigan. She is also an assistant professor at the Wayne State University School of Medicine, Department of Oncology. Her clinical and research interests are in molecular targeted therapy and immunotherapy in thoracic and head and neck malignancies, with a special focus in medical ethics. She serves as the site principal investigator (PI) for over 20 active clinical trials and enjoys collaborating with other PIs across the country and around the world. 

Professor Li Zhang is Professor of Medical Oncology, Director of Medical Oncology Department and Phase I Unit of Sun Yat-Sen University Cancer Centre (SYSUCC), Deputy Director of Lung Cancer Research Centre of SYSU. He is also the member of ASCO, CSCO, ESMO, IASLC, MASCC and Board of Directors of MASCC, Member of communication committee of IASLC. He completed training as a visiting fellow at the MD Anderson Cancer Centre; Fox Chase Cancer Centre, USA and Institut Gustave Roussy, Paris, France. Professor Zhang has published more than 200 clinical papers in top-tier journals like: Lancet, Journal of Clinical Oncology, Lancet Oncology, JAMA Oncology, Annals of Oncology, JTO. 

Janet Freeman-Daily, MS, Eng, is a retired aerospace systems engineer (trained at MIT and Caltech), freelance writer, speaker, and metastatic lung cancer patient/activist. She was diagnosed with advanced non-small cell lung cancer in May 2011, and progressed to stage 4 despite two lines of chemo-radiation. Fortunately, she learned about biomarker testing and clinical trials from other patients in online lung cancer communities. Thanks to a targeted therapy clinical trial, she has had no sign of cancer on scans since January 2012. Her focus is now on translating the experience and science of cancer for others. She writes an award-winning blog, cofounded and co-manages The ROS1ders, serves on staff for the IASLC STARS program, collaborates with lung cancer patient and advocacy organizations, and speaks as a research advocate at international oncology conferences, cancer research centers, biomedical and pharmaceutical companies, and government agencies. Her advocacy work focuses on ROS1 cancer, lung cancer, patient-centered outcomes, modernizing clinical trials, access to biomarker testing, data sharing, shared decision making, and goals of care. 

I am currently a Professor of Medicine, within the Department of Medicine, Section Hematology-Oncology at The University of Chicago. Until February 2021 I was the Chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori, Milano, Italy As a head, I lead the strategy for clinical and translational research in advanced and locally advanced NSCLC, SCLC, mesothelioma, and thymic malignancies.

As a medical oncologist, I have made research in precision medicine and in immuno-oncology. My main research interests have been mainly the development of new drugs and therapeutical strategies and biomarkers. I am the Chair of TYME (Italian network for research of thymic malignancies). I have contributed to over 200 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Annals of Oncology. I had several presentations at international congresses (ASCO, ESMO, ECCO, WCLC, and AACR). In the last five years, I was able to attract several grants (AIFA, AIRC, ERA-NET TRANS CAN, Berlucchi, and MISP from pharma companies, etc).

My education includes the degree and further specialization in Medical Oncology at the University of Study of Milan (110/110 cum laude) in 1995. I completed my training with an ESMO Clinical fellowship in 2009 at Christie's Hospital in Manchester (UK). I have been a member of EMA SAG (Scientific Advisory Group).

I am serving as ESMO Council and Chair of National Societies. I have been ESMO Italian National Representative for 5 years (2011-2017). I'm a member of several ESMO Taskforces (Public Policy extended Committee, Press Committee, and Women for Oncology). I am serving as ASCO Faculty Lung Cancer Track. I am the founder and honorary president of Women for Oncology Italy.

Dr. Masahiro Tsuboi is a Director of the Division of Thoracic Surgery and Oncology at the National Cancer Center Hospital East, Kashiwa, Japan, and a visiting Assistant Professor at the Department of Surgery, Yokohama City University Graduate school of Medicine in Yokohama, Japan. Dr Tsuboi is a past member of the IASLC Board of Directors, a past chair of the Lung Cancer Surgical Study Group (LCSSG)of the Japan Clinical Oncology Group (JCOG), and  a past member of the board of directors for the World Association of Bronchology and Interventional Pulmonology (WABIP). Dr. Tsuboi is the primary investigator and/or member of the study steering committee for numerous perioperative adjuvant and surgical clinical trials. He is a co-primary investigator—with Dr. Roy Herbst and Prof. Yi-Long Wu—for the ADAURA study, which is a randomized phase III study of osimertinib as postoperative adjuvant therapy in patients with stage IB–IIIA EGFR-mutation positive NSCLC.